Allogene Therapeutics ALLO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's EBITDA margin?
- Allogene Therapeutics (ALLO) reported EBITDA margin of -1,179,818.2% in Q4 2024.
- How has Allogene Therapeutics's EBITDA margin changed year-over-year?
- Allogene Therapeutics's EBITDA margin decreased by 257.5% year-over-year, from -330,040% to -1,179,818.2%.
- What is the long-term trend for Allogene Therapeutics's EBITDA margin?
- Over 3 years (2021 to 2024), Allogene Therapeutics's EBITDA margin has grown at a 1887.5% compound annual growth rate (CAGR), from -150.3% to -1,179,818.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.